基因癌症生物标记市场：现况分析与预测（2023-2030）

Genetic Cancer Biomarker Market: Current Analysis and Forecast (2023-2030)

出版日期: 2023年12月30日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格

简介目录

遗传癌症生物标记是 DNA 中的特定变化，可以显示癌症的风险增加或预测特定癌症的表现。这些生物标记透过识别与各种癌症相关的基因突变和变化，在早期检测、个人化治疗计划和预后评估中发挥重要作用。其他几个因素正在全球推动遗传癌症生物标记的发展，包括遗传疾病和不健康生活方式的增加。例如，根据BMC Public Health 的数据，2023 年7 月不健康生活方式的盛行率为：饮食为86.4%，饮酒为14.5%，烟草为6.0%，体力活动为72.2%，萤幕时间为42.3%，睡眠时间为63.9% 。

由于全球酒精和烟草盛行率不断上升，遗传癌症生物标记市场预计将以约 18.4% 的速度稳定成长。根据 2021 年全国药物使用与健康调查 (NSDUH)，2020 年有 2,950 万名 12 岁及以上的人患有酒精使用障碍 (AUD)。在预测期内，有几个因素正在推动市场成长，包括癌症发病率的急剧上升、对喉癌的认识不断提高、吸烟人口的增加、酗酒文化的兴起以及肿瘤学投资的增加。我们正在推动它。除此之外，透过遗传癌症生物标记物提高治疗效率可以加快治疗过程并提高准确性，这也稳步推动了遗传癌症生物标记市场的发展。例如，根据《美国癌症协会杂誌》报道，2021 年美国报告了 1,898,160 例新癌症病例和 608,570 例癌症死亡病例。

依癌症类型，市场分为乳癌、摄护腺癌、白血病等。 2022年全球基因癌症生物标记市场中，乳癌领域占最大份额。由于延迟怀孕、肥胖病例增加、老年人口增加以及吸烟、酗酒等不健康生活习惯的流行，该细分市场占据了市场主导地位。乳癌家族史也是这一细分市场的驱动因素。例如，根据世界卫生组织（WHO）的数据，2020年，全球有230万名女性被诊断出罹患乳癌，其中68.5万人死亡。因此，在癌症类型中，乳癌领域在2022年占据主要市场份额。

依科技分为组学、生物资讯学等。由于其在很短的时间内提供大量数据的潜在特点，预计 OMICS 行业将在预测期内占据重要的市场份额。组学技术专注于四大组学：基因组学、转录组学、蛋白质组学、代谢组学及其表观组学。该领域是由不断进步的技术推动的。例如，2023 年 4 月，Biomodal（原名 Cambridge Epigenetix）宣布了一种新的二重多组学解决方案，该解决方案揭示了将单个小样本中的遗传和表观遗传信息结合起来的能力。因此，在技术中，组学类别预计在预测期内表现出更高的复合年增长率。

为了更了解遗传癌症生物标记的市场介绍，市场为北美（美国、加拿大等北美地区）、欧洲（德国、英国、法国、西班牙、义大利等欧洲地区）、亚太地区（中国、日本、印度、亚太地区其他地区）及世界其他地区。在目前的 2022 年情境中，由于烟雾污染加剧、酒精消费增加以及开发有效遗传癌症生物标记的投资增加，北美将主导市场。政府机构已启动喉癌宣传计划，为患者提供有效的护理。例如，2023年7月，美国癌症研究协会和美国头颈学会在蒙特娄举办了第三届AACR-AHNS头颈癌联合会议，展示了最新的研究成果，并提供了生物学、检测、影像、预防、治疗等。 AACR 也向进行与头颈癌相关的有前景研究的研究人员提供研究资助。因此，按地区划分，北美将在 2022 年占据较大市场份额。

Genetic cancer biomarkers are specific changes in DNA that can indicate an increased risk of developing cancer or predict how a particular cancer might behave. These biomarkers play a crucial role in early detection, personalized treatment plans, and assessing prognosis by identifying genetic mutations or alterations associated with different types of cancer. Several other factors, such as rising genetic disorders and unhealthy lifestyles are leading drivers of genetic cancer biomarkers globally. For instance, according to the BMC Public Health, in July 2023, the prevalence of unhealthy lifestyles was 86.4% for diet, 14.5% for alcohol, 6.0% for tobacco, 72.2% for physical activity, 42.3% for screen time, and 63.9% for sleep duration.

The Genetic Cancer Biomarker Market is expected to grow at a steady rate of around 18.4% owing to the increased prevalence of alcohol and tobacco globally. According to the 2021 National Survey on Drug Use and Health (NSDUH), 29.5 million people ages 12 and older had Alcohol Use Disorder (AUD) in the year 2020. Several factors, including a surge in the incidence of cancer, increasing awareness regarding throat cancer, increasing smoking population, rising alcoholism culture, and increased investments in oncology departments are driving the growth of the market during the forecast period. Apart from this, accelerated treatment efficiency with genetic cancer biomarkers has resulted in faster treatment procedures and better accuracy which is also driving this market of genetic cancer biomarkers at a steady rate. For instance, according to the American Cancer Society Journals in 2021, 1,898,160 new cancer cases and 608,570 cancer deaths were reported in the U.S.

Based on cancer type, the market is segmented into breast, prostate, leukemia, and others. The breast cancer segment held the maximum share in the global market of genetic cancer biomarkers in 2022. This segment dominated the market because of the delayed pregnancies, rising cases of obesity, increasing geriatric population, and increased prevalence of ill lifestyles including smoking, alcoholism, and unhealthy lifestyles among people. A family history of breast cancer is also a propelling factor for this segment. For instance, according to the World Health Organization in 2020, there were 2.3 million women diagnosed with breast cancer and 685,000 deaths globally. Thus, amongst cancer types, the breast cancer segment held a significant share of the market in 2022.

Based on technology, the market is categorized into OMICS, bioinformatics, and others. The OMICS segment is expected to hold a significant share of the market in the forecast period owing to its potential feature of providing a huge amount of data in a very short period. OMICS technology focuses on the four big omics, i.e., genomics, transcriptomics, proteomics, and metabolics, and their epiomics. This segment is propelled by rising technological advancements. For instance, in April 2023, Biomodal, formerly known as Cambridge Epigenetix, launched its new duet multiomics solution, which reveals the combinatorial power of genetic and epigenetic information from a single low-volume sample. Thus, amongst technology, the OMICS category is expected to witness higher CAGR during the forecast period.

For a better understanding of the market adoption of genetic cancer biomarkers, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and the Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America is dominating the market in the current scenario of 2022 due to the increasing smoke pollution, increasing alcohol consumption, and rising number of investments in developing effective genetic cancer biomarkers. Government organizations are initiating throat cancer awareness programs to provide efficient care to patients. For example, In July 2023, the American Association for Cancer Research and the American Head and Neck Society organized the third AACR-AHNS Joint Conference on Head and Neck Cancer in Montreal to present their latest research and provide critical updates on head and neck cancer biology, detection, imaging, prevention, and therapy, among other topics. The AACR also awards research grants to investigators pursuing promising research related to head and neck cancer. Thus, amongst regions, North America held a significant share of the market in 2022.

Some of the major players operating in the market include: F. Hoffmann-La Roche Ltd.; Thermo Fisher Scientific Inc.; QIAGEN N.V.; Illumina Inc.; Bio-Rad Laboratories Inc.; Exact Sciences; Merck KGaA; Pfizer Inc.; Seegene Technologies Inc.; Siemens Healthineers.

1 MARKET INTRODUCTION

1.1. Market Definitions
1.2. Main Objective
1.3. Stakeholders
1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

2.1. Research Process of the Genetic Cancer Biomarker Market
2.2. Research Methodology of the Genetic Cancer Biomarker Market
2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE GENETIC CANCER BIOMARKER MARKET

6 GENETIC CANCER BIOMARKER MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY CANCER TYPE

7.1. Breast Cancer
7.2. Prostate Cancer
7.3. Leukemia Cancer
7.4. Others

8 MARKET INSIGHTS BY TECHNOLOGY

8.1. OMICS
8.2. Bioinformatics
8.3. Others

9 MARKET INSIGHTS BY REGION

9.1. North America
- 9.1.1. U.S.
- 9.1.2. Canada
- 9.1.3. Rest of North America
9.2. Europe
- 9.2.1. Germany
- 9.2.2. U.K.
- 9.2.3. France
- 9.2.4. Italy
- 9.2.5. Spain
- 9.2.6. Rest of Europe
9.3. Asia-Pacific
- 9.3.1. China
- 9.3.2. Japan
- 9.3.3. India
- 9.3.4. Rest of Asia-Pacific
9.4. Rest of World